Skip to main content
    N

    Nutex Health Inc (NUTX)

    Official site

    HEALTHCARE • MEDICAL CARE FACILITIES • NASDAQ

    $174.51
    +4.81 (+2.83%)

    Market Cap: $1.19B

    Last updated: Nov 17, 2026 at 4:15 PM ET

    Nutex Health Inc (NUTX) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Nutex Health (NUTX) has a market cap of $1.19B and an enterprise value of $1.27B. Its return on invested capital of 32.44% compares with a 8.61% median across 8 similar companies. Revenue fell 18.82% over the last 12 months from the 12 months before.

    Total Valuation

    Enterprise value is 6.72% above the market cap, as debt exceeds cash.

    Market Cap$1.19B
    Enterprise Value$1.27B
    Latest price (Nov 17, 2026)$174.51

    Key Dates

    The next earnings report is expected on Mar 3, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 3, 2027 (expected)
    Last Earnings DateNov 5, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.19% in the quarter ended Sep 30, 2026 and grew 12.33% a year over 2 years.

    Shares Outstanding6.86M
    Shares Change (YoY)-2.99%
    Shares Change (QoQ)+0.19%
    Share Count Growth (2Y CAGR)+12.33%

    Valuation Ratios

    Sales and book value multiples are 1.5x and 2.7x.

    P/E Ratio7.7x
    Forward P/E6.2x
    P/S Ratio1.5x
    Forward P/S1.4x
    P/B Ratio2.7x
    P/TBV Ratio3.0x
    P/FCF Ratio4.8x
    P/OCF Ratio4.6x
    PEG Ratio0.4

    Valuation history and multiples

    Enterprise Valuation

    Counting debt and cash, the company is valued at 3.8x EBITDA and 5.1x free cash flow.

    EV / Earnings5.5x
    EV / Sales1.6x
    EV / EBITDA3.8x
    EV / EBIT4.1x
    EV / FCF5.1x

    Price Statistics

    The stock is up 62.93% over 52 weeks and trades 13.40% below its 50-day average.

    Beta (1Y)1.67
    52-Week Change+62.93%
    1-Month Change-8.75%
    3-Month Change-8.45%
    6-Month Change+38.07%
    5-Year Change-66.62%
    10-Year Change-95.89%
    Total Return (1Y)+62.93%
    Total Return (3Y CAGR)+71.32%
    Total Return (5Y CAGR)-21.90%
    Return vs SPY (1Y)+64.36%
    Max Drawdown (1Y)-54.32%
    Max Drawdown (3Y)-87.94%
    Sharpe Ratio (1Y)0.64
    Correlation with SPY (1Y)0.26
    50-Day Average$201.51
    200-Day Average$152.18
    52-Week Range$83.99 to $226.16
    RSI (14 Days)41.6
    Average Volume (20 Days)139.96K

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 4.76x current liabilities, and total debt is 0.76x shareholder equity.

    Current Ratio4.76x
    Quick Ratio4.72x
    Debt / Equity0.76x
    Debt / EBITDA0.99x
    Debt / FCF1.33x
    Interest Coverage16.22x

    Returns and Efficiency

    Return on invested capital is 32.44% over the last 12 months, against a 5-year average of -30.14%.

    Return on Equity (ROE)53.50%
    Return on Assets (ROA)22.57%
    Return on Invested Capital (ROIC)32.44%
    Return on Capital Employed (ROCE)34.61%
    ROE (5Y Average)-49.75%
    ROA (5Y Average)-6.87%
    ROIC (5Y Average)-30.14%
    Asset Turnover0.80x
    Inventory Turnover42.68x
    Receivables Turnover2.22x
    Cash Conversion Cycle150 days

    Taxes

    Income tax took 20.22% of pretax income over the last 12 months.

    Income Tax (TTM)$59.05M
    Effective Tax Rate20.22%

    Scores

    NUTX has an Altman Z-Score of 3.63, in the safe zone above 2.99, and a Piotroski F-Score of 8 of 9, in the strong band of 8 or 9.

    Altman Z-Score3.63
    Altman Z ZoneSafe
    Piotroski F-Score8 of 9
    Piotroski StrengthStrong

    Income Statement

    Revenue was $796.53M over the last 12 months.

    Revenue$796.53M
    Revenue Growth (YoY)-18.82%
    Gross Profit$380.67M
    Operating Income$311.00M
    Pretax Income$292.08M
    Net Income$233.03M
    EBITDA$332.89M
    EBIT$311.27M
    Reported EPS (TTM)$22.65

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 42.29% of the $1.03B in total assets.

    Cash and Equivalents$249.91M
    Total Debt$330.00M
    Net Debt$80.09M
    Net Debt Per Share$11.67
    Working Capital$500.30M
    Shareholder Equity$435.57M
    Book Value Per Share$63.49
    Tangible Book Value$401.39M
    Tangible Book Per Share$58.51
    Total Assets$1.03B
    Total Liabilities$491.47M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $10.35M of capital spending, operating cash flow left $248.10M of free cash flow.

    Operating Cash Flow$258.45M
    Capital Expenditures$10.35M
    Free Cash Flow$248.10M
    FCF Per Share$36.23
    Depreciation and Amortization$21.62M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is 39.04%, against a 5-year average of -17.63%.

    Gross Margin47.79%
    Operating Margin39.04%
    Pretax Margin36.67%
    Net Margin29.26%
    EBITDA Margin41.79%
    EBIT Margin39.08%
    FCF Margin31.15%
    Gross Margin (5Y Average)33.36%
    Operating Margin (5Y Average)-17.63%
    Net Margin (5Y Average)-24.74%

    Growth

    Revenue grew 58.62% a year over 3 years.

    Revenue Growth (3Y CAGR)+58.62%
    Revenue Growth (5Y CAGR)+26.14%
    FCF Growth (3Y CAGR)+89.70%
    FCF Growth (5Y CAGR)+57.32%

    Revenue and profit by year

    Dividends and Yields

    NUTX does not pay a dividend. Its free cash flow yield is 20.72%.

    Earnings Yield12.99%
    FCF Yield20.72%
    Buyback Yield4.23%
    Shareholder Yield11.40%

    Stock Splits

    The last split was a 1-for-10 reverse split on Jul 3, 2024.

    Last Split DateJul 3, 2024
    Split TypeReverse split
    Split Ratio1:10

    Peer Position

    Against 7 similar companies, NUTX has the lowest P/E.

    P/E Ratio7.7x vs 28.6x median
    P/S Ratio1.5x vs 1.6x median
    ROIC32.44% vs 8.61% median
    Revenue Growth (Trailing 4 Quarters, YoY)-18.82% vs +16.84% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 4.99% and EPS growth at 30.61% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+4.99%
    EPS Growth Forecast (2Y CAGR)+30.61%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewFairly valued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About NUTX

    What is NUTX's market cap?

    Nutex Health has a market cap of $1.19B. Its enterprise value, which adds debt and subtracts cash, is $1.27B.

    What is NUTX's P/E ratio?

    Nutex Health has a trailing P/E ratio of 7.7x and a forward P/E of 6.2x.

    How many shares of NUTX are outstanding?

    Nutex Health has 6.86M shares outstanding. The count is down 2.99% from a year earlier.

    Does NUTX pay a dividend?

    No. Nutex Health does not pay a dividend.

    How much debt does NUTX have?

    Nutex Health has $330.00M of total debt and $249.91M of cash and equivalents, a net debt position of $80.09M.